Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities (2018 - 2026)

Adaptive Biotechnologies has reported Total Non-Current Liabilities for 9 years, with the latest figure at $281.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.14% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY) and the FY2025 annual result came in at $287.7 million, down 14.59% from the prior year.
• Total Non-Current Liabilities eased to $281.7 million in Q1 2026 per ADPT's latest filing, from $287.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $343.4 million in Q2 2024 and troughed at $240.4 million in Q2 2023.
• A 5-year average of $294.0 million and a median of $287.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities declined 15.63% in 2022, then surged 42.85% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $267.2 million in 2022, then fell by 10.01% to $240.4 million in 2023, then surged by 40.13% to $336.9 million in 2024, then dropped by 14.59% to $287.7 million in 2025, then dropped by 2.1% to $281.7 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $281.7 million, $287.7 million, and $286.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.